QNCX

Quince Therapeutics, Inc.

1.29 USD
+0.01 (+0.78%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Quince Therapeutics, Inc. stock is down -3.01% since 30 days ago. The next earnings date is Mar 18, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 64.29% of the previous 19 March’s closed higher than February.

About Quince Therapeutics, Inc.

Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's and other degenerative diseases. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor.